Rakuten Medical

Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment using ASP-1929 for Recurrent Head and Neck Cancer in India

by

SAN DIEGO, May 22, 2023 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical trial (ASP-1929-301/ClinicalTrials.gov … Read more

Rakuten Medical to Present New Data of Alluminox™ Treatment using ASP-1929 in Combination with anti-PD-1 at AHNS 2023

by

SAN DIEGO, May 12, 2023 /PRNewswire/ — Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announced that the abstract ‘Safety and efficacy findings from a phase 1b/2 open-label study of a novel combination of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced … Read more